Pfizer CEO Albert Bourla, Ph.D., has pulled back the curtain on his $1.25 billion bet on a PD-1xVEGF bispecific, revealing ...

As President Donald Trump vows to bridge the drug pricing gap between the U.S. and other developed countries with his “most ...

Pfizer's CEO discussed the extensive due diligence the company has conducted on the 3SBio PD-1xVEGF deal. | Pfizer's CEO ...

Pfizer Inc. (NYSE:PFE) is one of the best wide moat stocks to buy now. On June 9, Pfizer, along with other drug manufacturers ...

STORY: Pfizer CEO Albert Bourla said Monday that he and other drug companies met with the Trump administration to discuss ...

Pfizer and other drug companies have met with the Trump administration to discuss lowering U.S. drug prices but no ...

(Reuters) -Pfizer and other drug companies have met with the Trump administration to discuss lowering U.S. drug prices but no ...

Industry sources reveal drug companies have stopped negotiating listings on the PBS and in some cases are considering not ...

Pfizer and other drug companies have met with the Trump administration to discuss most-favored-nation pricing but no commitments have been made, Chief Executive Albert Bourla said on Monday at an ...

President Isaac Herzog and Genesis Prize Foundation chairman Stan Polovets presented the award, praising Milei as a “moral ...

CEO Albert Bourla has reportedly said that the company has made no commitments during its meeting with the Trump ...

Deep Apple Therapeutics Inc. could bring in as much as $812 million in a new collaboration and license deal with Novo Nordisk A/S. The total includes an unspecified up-front payment, research costs ...